G&E Herbal Biotechnology , Ltd. Overview
Latest ROE for G&E Herbal Biotechnology , Ltd.: 9.84% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow9.84%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 4911.TWO is 9.84%. That is below the Healthcare sector average of 11.15%. Investors often review this figure alongside G&E Herbal Biotechnology , Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 4911.TWO currently prints 9.84% for ROE, while the sector average sits near 11.15%. That is roughly 11.8% below the sector mean. Large gaps often invite a closer look at G&E Herbal Biotechnology , Ltd.'s growth, margins, and balance sheet.
Return on Equity shows how effectively G&E Herbal Biotechnology , Ltd. converts resources into returns. At 9.84%, 4911.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 4911.TWO's ROE (9.84%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack G&E Herbal Biotechnology , Ltd.'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
